Clinical Trial Update: Study of INKmune in Patients With mCRPC (CaRe Prostate) [Phase 1, Phase 2]

View source ↗

Summary

The update notes the completion of a Phase 1/2 study of INKmune in metastatic castration-resistant prostate cancer (CaRe Prostate) sponsored by Inmune Bio.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• INKmune (INKmune)

Snippet

Sponsor: Inmune Bio, Inc. | Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED